SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai ($BBAI) is trending amid high volume and community excitement, fueled by speculation of upcoming government contracts. A recent congressional disclosure of stock purchases by a politician and Goldman Sachs increasing their holdings has further amplified the buzz. Traders are closely watching key resistance levels, anticipating a potential short squeeze and aiming for significant gains.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the company received UK regulatory approval for its acquisition of Oxford Ionics, potentially accelerating its technology roadmap; the community is actively discussing the deal's implications and future catalysts such as the Quantum World Congress. Bullish sentiment is fueled by analyst upgrades, increased price targets, and perceived momentum in the quantum computing sector, while bears question the valuation and long-term profitability.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as community members discuss its potential for a significant run, drawing comparisons to sector peers and highlighting its squeeze potential. Bullish sentiment is fueled by increasing volumes and speculation around the company's transition into AI/HPC, with some anticipating news of partnerships and significant upside. Short squeeze speculation continues to drive community engagement.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors discuss the potential for a short squeeze and long-term growth in the quantum computing sector. Community members are actively debating the stock's valuation and future prospects amidst broader discussions about growing enterprise adoption of quantum technologies and advancements from competitors. Some traders are pointing to technical indicators and potential breakout levels, while others express skepticism, citing dilution concerns.

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

Turbo Energy (TURB) is trending due to a significant $53 million contract to deploy solar storage projects, sparking excitement about the company's growth potential in the energy sector. Community discussions revolve around the stock's volatile price action, potential short squeeze opportunities, and comparisons to other high-flying stocks. Some traders are also noting its low float, which may contribute to price swings.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending amid an analyst upgrade from UBS and increasing optimism surrounding new products and NIO Day. The community is focused on ES8 deliveries and the potential for a short squeeze, drawing comparisons to other EV manufacturers like LCID. Traders are watching key resistance levels, with some suggesting the stock could see a significant surge if it breaks through.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is experiencing significant volatility and trending due to a potential short squeeze, with community members noting its small float and comparing it to other recent high-momentum stocks. Chatter suggests possible accumulation, a double bottom formation, and increasing volume during power hour. Some are also discussing its low market cap relative to its value.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending amid positive sentiment following its latest earnings report, with discussions focusing on the company's revenue growth and raised guidance. The community highlights the company's popularity with a younger demographic and its ongoing expansion plans as reasons to remain bullish. Some investors are debating whether the stock is currently overvalued, while others are anticipating further gains.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

Marathon Digital (MARA) is trending as traders discuss its potential for a short squeeze, while some express frustration with the stock's performance compared to other miners like CLSK and RIOT. Community members are debating whether MARA is undervalued, citing its Bitcoin holdings and potential AI integration, while others criticize the management and potential dilution.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

APPS is trending as community members assess the potential impact of a newly announced share offering on the stock's future trajectory, with some expressing concern about dilution.  Positive revenue guidance and discussion around debt are also key talking points. Some traders are considering this a buying opportunity, while others express frustration.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates

Nektar (NKTR) delivered earnings and revenue surprises of +5.75% and +3.66%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates

Rigel (RIGL) delivered earnings and revenue surprises of +66.50% and +28.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Nektar Gears Up to Report Q2 Earnings: What's in the Cards?

NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.

Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street analysts sharply upgraded their outlook on Nektar Therapeutics on Wednesday following positive topline results from the company’s Phase 2b REZOLVE-AD trial of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.Nektar Therapeutics’ stock closed Wednesday up 19.1% at $29.12 and added another 1.1% after hours to $29.43.Jefferies lifted its price target from $2 to $69, citing improved confidence in rezpegaldesleukin’s efficacy and safety in what it described as an “enormous disease space.”&nbsp;The firm maintained a ‘Buy’ rating.Additionally, BTIG raised its target to $100 from $60, calling the stock a “pound the table BUY” and noting that all three dose arms achieved statistical significance across primary and secondary endpoints at 16 weeks.&nbsp;BTIG analysts said the “robust” data support rezpegaldesleukin’s status as a novel mechanism of action with&nbsp;the potential to outperform current therapies.Meanwhile, H.C. Wainwright was the most bullish, increasing its target from $6.50 to $120 and calling the results “paradigm-shifting.”&nbsp;The firm said rezpeg’s highly differentiated profile could reshape the atopic dermatitis treatment landscape and noted further improvement may come in the 36-week maintenance data expected in Q1 2026.Nektar said its primary 16-week induction data&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nektar-therapeutics-announces-positive-data-from-eczema-drug-in-mid-stage-trial/chm40c0RR3i">met its primary endpoint</a>, with a statistically significant improvement in Eczema Area and Severity Index (EASI) in all dose arms versus placebo.&nbsp;The company also met its secondary endpoints, which include EASI-75, EASI-50, BSA score, vIGA-AD 0/1, Itch NRS, and EASI-90 at the highest dose.&nbsp;Safety was consistent with previous data, and&nbsp;blood biomarker data showed strong on-target, dose-dependent activity.The results will be shared at a medical conference later in 2025. The company expects to report Phase 2b data for rezpeg in alopecia areata in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said that Nektar could touch $100 as early as tomorrow.&nbsp;<stembedurl>https://stocktwits.com/LFG2030/message/619030106</stembedurl>Another speculated that, barring an immediate equity offering, the stock might reach $40 in the next session.<stembedurl>https://stocktwits.com/Majlo/message/619029852</stembedurl>Others remained cautious, noting&nbsp;that dilutive financings often follow such rallies.&nbsp;One user said an offering was likely “incoming,” potentially in the $15 range.<stembedurl>https://stocktwits.com/BIGPHILLY/message/619028491</stembedurl>Still, some bulls pushed back, dismissing near-term offering concerns as "bear hopium" and predicting a move to $49 to fill the gap, with all-time highs (ATH) as the next target.<stembedurl>https://stocktwits.com/Da_Closer/message/619027710</stembedurl>Nektar’s stock has doubled its value so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, on October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside

The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis. 

Equity

NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study

Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.

Shares of Nektar Therapeutics (NKTR) more than doubled on Tuesday afternoon after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.nektar.com/news-releases/news-release-details/rezolve-ad-phase-2b-study-rezpegaldesleukin-meets-primary-and">announced</a> that its mid-stage study evaluating Rezpegaldesleukin in atopic dermatitis demonstrated improvement in area affected and severity.The global Phase 2b study is being conducted in 393 patients with moderate-to-severe atopic dermatitis. The company announced that, at week 16, patients who received Rezpegaldesleukin showed improvement in eczema area and severity score from baseline, as compared to placebo, using a widely used index.The trial also demonstrated that Rezpegaldesleukin reduced disease severity by as much as 90% or more with higher doses of the drug.Atopic dermatitis is the most common type of eczema, affecting approximately 30 million people in the U.S., according to Nektar. It is characterized by a defect in the skin barrier, which allows allergens and other irritants to enter the skin, leading to an immune reaction and inﬂammation.Rezpegaldesleukin is an investigational therapy that may address the underlying immune system imbalance in people with many autoimmune and inflammatory conditions.It targets the interleukin-2 receptor complex in the body to stimulate the proliferation of powerful inhibitory immune cells known as regulatory T cells. By activating these cells, Rezpegaldesleukin aims to restore the immune system's balance.The company is now looking forward to reporting results from its trial of Rezpegaldesleukin in alopecia areata, an autoimmune disease that causes hair loss, in the fourth quarter of this year.Following the update from the company, H.C. Wainwright raised the firm's price target on Nektar to $120 from $6.50 while keeping a ‘Buy’ rating on the shares.On Stocktwits, retail sentiment around Nektar jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume increased from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:628/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_12_04_09_PM_png_6458c1b61c.webp" alt="NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits" width="628" height="66"><figcaption>NKTR's Sentiment Meter and Message Volume as of 12 p.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the user to jump as much as 150% later today.<stembedurl>https://stocktwits.com/US_Bull/message/618826543</stembedurl><a href="https://stocktwits.com/symbol/NKTR">NKTR stock</a> is up by 66% this year and by about 32% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/jerome-powell-tells-congress-fed-can-wait-on-rate-cuts-despite-pressure-from-trump/chm4hMMRR3h">Jerome Powell Tells Congress Fed Is ‘Well Positioned To Wait’ On Rate Cuts Despite Mounting Pressure From Trump</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further

Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16.

Nektar Therapeutics shares jumped 35.3% in&nbsp;extended trading Monday after the company said it&nbsp;would release topline results from its Phase 2b REZOLVE-AD study of rezpegaldesleukin for atopic dermatitis on Tuesday.The stock closed Monday’s regular session up 12.1% at $9.54.The experimental treatment is called NKTR-358 or REZPEG. It's a first-in-class regulatory T-cell (Treg) stimulator in development for autoimmune and inflammatory skin diseases.Nektar will hold an investor webcast at 8:15 a.m. ET on June 24 to discuss the 16-week induction data from the global trial.The stock reaction follows CEO Howard Robin's remarks in May that the company was on track to deliver trial results in June, positioning rezpegaldesleukin to emerge as an “important novel mechanism” to treat patients with chronic autoimmune disorders.The company also reiterated that topline data from a separate Phase 2 trial in alopecia areata are expected by December.In its most recent earnings report, Nektar posted a Q1 adjusted loss of&nbsp;$0.22 per share, wider than the consensus estimate of&nbsp;$0.19 loss per share. Revenue came in at $10.5 million, below analysts' expectations of $15.36 million.Robin also said Nektar is advancing other pipeline assets, including NKTR-0165 for multiple sclerosis and ulcerative colitis and a bispecific antibody candidate, NKTR-0166, both targeting the TNFR2 receptor.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 4,600% surge in 24-hour message volume.One user expects shares of Nektar to climb to the $14–$15 range overnight.&nbsp;<stembedurl>https://stocktwits.com/RealBobbyAxelrod/message/618755635</stembedurl>Another user noted the strong after-hours move likely reflected optimism, but expressed uncertainty about holding the position, saying they were tempted to take some profits.<stembedurl>https://stocktwits.com/Patrick2343/message/618743686</stembedurl>The stock has declined 33.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Low-angle view of a logo on a facade at the headquarters of Nektar Therapeutics, a biopharmaceutical company located on 3rd Street, in the Mission Bay District of San Francisco, California, October 29, 2018. (Photo by Smith Collection/Gado/Getty Images)

Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away

Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

NKTR
Nektar Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NKTR News

NKTR Nektar Therapeutics